Market Overview

UPDATE: Piper Jaffray Raises Amgen PT to $107, Says Short Term Strength Expected From Omontys Failure

Share:
Related AMGN
Stay Of Court Injunction A Mild Positive For Regeneron
Regeneron Gets 'Encouraging' Judicial Decision, Could Still Lose Appeal
What Makes Amgen A Compelling Buy In 2017? (Seeking Alpha)

In a report published Sunday, Piper Jaffray reiterated an Overweight rating for Amgen (NASDAQ: AMGN) and raised its price target from $104 to $107.

In the report, Piper Jaffray wrote, "We remain Overweight and are increasing our price target to $107 from $104 following the safety recall of Affymax's Omontys. We believe the recall has positive near and long term implications on Amgen's Epogen, translating into an additional $300-$500mn per year through 2016. In the short-term, we believe both Fresenius Medical and the MDOs/SDOs with Omontys supply agreements will return to Epogen. Longer term, we believe the Omontys recall strengthens Epogen's competitive position, as we believe it could increase the regulatory hurdle for Roche's Mircera and biosimilars at FDA, some of which have already shown unique safety signals. We believe Phase III data from TVEC in malignant melanoma (1H13) and trebananic (AMG386) PFS data in ovarian cancer (mid-2013) are Amgen's next clinical catalysts. As we and the Street assign low probability of success for these trials, we see limited downside but significant upside if data is positive."

Amgen closed Friday at $86.82.

Latest Ratings for AMGN

DateFirmActionFromTo
Feb 2017Bank of AmericaUpgradesNeutralBuy
Dec 2016OppenheimerInitiates Coverage OnOutperform
Nov 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Omontys Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!